Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A humanized monoclonal antibody for the treatment of colorectal cancer.

Etymologies

from Wiktionary, Creative Commons Attribution/Share-Alike License

-tu- +‎ -zu- +‎ -mab

Examples

  • In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.

    The Earth Times Online Newspaper

  • In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.

    The Earth Times Online Newspaper

  • The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.

    The Earth Times Online Newspaper

  • In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.

    The Earth Times Online Newspaper

  • The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.

    The Earth Times Online Newspaper

  • In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.

    The Earth Times Online Newspaper

  • The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.

    The Earth Times Online Newspaper

  • The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.

    The Earth Times Online Newspaper

  • (Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, selectively delivers SN-38 to human colon carcinoma in animal models as an effective new therapy.

    Health News from Medical News Today

  • In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer.

    Health News from Medical News Today

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.